TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge

Imaoka, Haruki; Campbell, Heather; Babirad, Irene; Watson, Rick; Mistry, Mahek; Sehmi, Roma; Gauvreau, Gail M.

doi:10.1111/j.1365-2222.2011.03816.x

Cited by 62 publications

(36 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40 The sputum samples were processed by selecting the mucus plugs, mixing with 4 parts 0.1% dithiothreitol and Dulbecco PBS, and filtered through a 52-mm nylon mesh. 41 The cells in the filtrate were pelleted and resuspended in Dulbecco PBS. Cytospin preparations were prepared on glass slides and stained with Diff-Quik (American Scientific Products, McGaw Park, Ill) for differential counts expressed as percentage means of duplicate slides (400 cells counted per slide).…”

Section: Sputum Induction and Cell Isolationmentioning

confidence: 99%

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia

Smith

Chen

Kjarsgaard

et al. 2016

Journal of Allergy and Clinical Immunology

382

349

View full text Add to dashboard Cite

show abstract

Section: Sputum Induction and Cell Isolationmentioning

confidence: 99%

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia

Smith

Chen

Kjarsgaard

et al. 2016

Journal of Allergy and Clinical Immunology

382

349

View full text Add to dashboard Cite

show abstract

“…The aim is to reduce the levels of mRNA by preventing the specific gene transcription needed for cytokine receptor production. TPI ASM-8, an antisense oligonucleotide, targets against CCR3, which mediates the effect of some eosinophil chemoattractant [51]. TPI ASM-8 has been shown to significantly reduce allergen airway eosinophilia in 14 stable, mild allergic asthmatics in a dose-dependent manner [52,53].…”

Section: New Approachesmentioning

confidence: 99%

Anti-interleukin-5 therapy in severe asthma

Garcia

Taillé

Laveneziana

et al. 2013

European Respiratory Review

111

View full text Add to dashboard Cite

Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms, exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal exacerbations.This as yet significant minority of individuals present with severe asthma and have persisting daily symptoms, and exacerbations despite compliance with high doses of inhaled steroids and additional treatment. For more than a decade, the pharmacological management of patients with severe asthma has focused on evaluating specific cytokines. The rationale of this approach is based on the distinguished key role played by eosinophils in the asthma inflammatory processes. Eosinophils are recruited from the circulation to airways where they cause airway damage via different mechanisms. Eosinophils are regulated in terms of their recruitment, activation, growth, differentiation and survival by interleukin (IL)-5. Abundant data from in vitro experiments, animal models and clinical trials has confirmed that IL-5 inhibition may be an effective approach for the treatment of asthma, especially severe asthma. Interfering with eosinophil function or reducing their numbers has been one of the most important goals of therapeutic monoclonal antibodies, which target cytokine receptor interactions in asthma, particularly IL-5. This review will consider new treatments options for severe asthma, particularly those targeting IL-5, that have already been evaluated in clinical trials in asthmatic patients. @ERSpublications Rationale, recent advances and future developments of anti-IL-5 therapy in patients with severe asthma http://ow.ly/n3viv

show abstract

“…In a small clinical study with patients with mild asthma, the drug was safe and well tolerated. It attenuated the allergen-induced increase in target gene mRNA, allergen-induced sputum eosinophils, and the early and late asthmatic responses [40,41]. It also reduced the number of CD34(+) CCR3(+) cells and CD34 (+) IL-5Rα(+) cells and the proportion of CD34(+) cells expressing IL-5Rα.…”

Section: Targeting Eosinophil Chemokine Receptorsmentioning

confidence: 92%

Chemokine Receptors in Allergy, Inflammation, and Infectious Disease

Pease

Horuk

2014

Topics in Medicinal Chemistry

View full text Add to dashboard Cite

Chemokines play an important role in disease by virtue of their effects on immune cells. They mediate their biological effects by acting on G-proteincoupled receptors, which represent one of the most druggable classes of proteins. In this review we will examine the role of chemokines in autoimmunity and inflammation by concentrating on the part they play in the pathophysiology of several diseases including asthma, multiple sclerosis, and rheumatoid arthritis. We will describe the various strategies that pharmaceutical companies have come up with to block the effect of chemokines in driving these disease processes and how they have fared in the clinic. We will also briefly discuss the repurposing of chemokine receptor antagonists in new indications.

show abstract

TPI ASM8 reduces eosinophil progenitors in sputum after allergen challenge

Cited by 62 publications

References 26 publications

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia

Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia

Anti-interleukin-5 therapy in severe asthma

Chemokine Receptors in Allergy, Inflammation, and Infectious Disease

Contact Info

Product

Resources

About